Superior Planning, LLC’s Viridian Therapeutics VRDN Stock Holding History

Superior Planning, LLC’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.26K	Buy	+61	New	+$1.3K	﹤0.01%	1702

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Davern Capital Partners Ny, New York $514M AUM 16.9% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Superior Planning, LLC's VRDN Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 61 shares worth $1.26K. The stake represents ﹤0.01% of the portfolio and ranks #1702 among its holdings.

120 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

Superior Planning, LLC held 61 shares of Viridian Therapeutics worth $1.26K as of Q3 2026.
Viridian Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Viridian Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1702 holding.
120 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.